(Press-News.org) Lars H. Lund, M.D., Ph.D., of the Karolinska Institutet, Stockholm, Sweden, and colleagues conducted a study to examine whether beta-blockers are associated with reduced mortality in heart failure patients with preserved ejection fraction (a measure of how well the left ventricle of the heart pumps with each contraction).The study appears in the November 19 issue of JAMA, a cardiovascular disease theme issue.
Up to half of patients with heart failure have normal or near-normal ejection fraction, termed heart failure with preserved ejection fraction (HFPEF). The risk of death in HFPEF may be as high as in heart failure with reduced ejection fraction (HFREF), but there is no proven therapy. Beta-blockers improve outcomes in HFREF and may be beneficial in HFPEF, but data are sparse and inconclusive, and beta-blockers are currently not indicated for treating HFPEF, according to background information in the article.
The researchers used data from the Swedish Heart Failure Registry, which includes 67 hospitals with inpatient and outpatient units and 95 outpatient primary care clinics in Sweden. This analysis included 41,976 patients, 19,083 patients with HFPEF. Of these, 8,244 were matched 2:1 based on age and beta-blocker use, yielding 5,496 treated and 2,748 untreated patients with HFPEF. Another analysis involved 22,893 patients with HFREF, of whom 6,081were matched, yielding 4,054 treated with beta-blockers and 2,027 untreated patients.
In the matched HFPEF cohort, 5-year survival was 45 percent vs 42 percent for treated vs untreated patients, with 2,279 (41 percent) vs 1,244 (45 percent) total deaths, and a seven percent reduction in the risk of death. Beta-blockers were not associated with reduced combined mortality or heart failure hospitalizations: 3,368 (61 percent) vs 1,753 (64 percent) total for first events. In the matched HFREF cohort, beta-blockers were associated with reduced mortality and also with reduced combined mortality or heart failure hospitalization.
"In patients with HFPEF, use of beta-blockers was associated with lower all-cause mortality but not with lower combined allcause mortality or heart failure hospitalization," the authors write. "Beta-blockers in HFPEF should be examined in a large randomized clinical trial."
INFORMATION:
(doi:10.1001/jama.2014.15241; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Searching for Treatments of Heart Failure with Preserved Ejection Fraction - Matching the Data to the Question
In an accompanying editorial, Susan Cheng, M.D., M.P.H., and Marc A. Pfeffer, M.D., Ph.D., of Brigham and Women's Hospital, Boston, write that by design, administrative databases, such as the one used in this study, offer limited ability to provide complete information about potentially important confounders.
"Thus, an attempt to use administrative data to probe the potential efficacy of a therapy is a mismatch of the data to the question. However, for most questions in medicine, only incomplete data are available to guide diagnostic and therapeutic decisions, and observational studies may have a role in assisting with treatment options. As the authors also conclude, more definitive information about whether beta-blocker therapy is effective for preventing important outcomes in HFPEF requires well-designed and well conducted randomized clinical trials."
(doi:10.1001/jama.2014.15358; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
Duk-Woo Park, M.D., of the University of Ulsan College of Medicine, Seoul, Korea, and Manesh R. Patel, M.D., of the Duke Clinical Research Institute, Durham, N.C., and colleagues investigated the incidence, extent, and location of obstructive non-infarct-related artery (IRA) disease and compared 30-day mortality according to the presence of non-IRA disease in patients with ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack). Obstructive non-IRA disease is blockage in arteries not believed to be the cause ...
Stefanie Schulz-Schupke, M.D., of the Deutsches Herzzentrum Munchen, Technische Universitat, Munich, Germany and colleagues assessed whether vascular closure devices are noninferior (not worse than) to manual compression in terms of access site-related vascular complications in patients undergoing diagnostic coronary angiography. The study appears in the November 19 issue of JAMA, a cardiovascular disease theme issue.
Percutaneous (through the skin) coronary angiography and interventions have become a cornerstone in the diagnosis and treatment of coronary artery disease. ...
Giulio Conte, M.D., of the Heart Rhythm Management Centre, UZ Brussel-VUB, Brussels, Belgium and colleagues investigated the clinical significance of repeat testing after puberty in asymptomatic children with a family history of Brugada syndrome who had an initial negative test earlier in childhood. Brugada syndrome is a genetic disease that is characterized by abnormal electrocardiogram findings without structural heart disease and an increased risk of sudden cardiac death. The study appears in the November 19 issue of JAMA, a cardiovascular disease theme issue.
Brugada ...
DURHAM, N.C. - A blocked artery causes a deadly kind of heart attack known as STEMI, and a rapid response to clear the blockage saves lives.
But in more than half of cases studied recently by Duke Medicine researchers, one or both of the patient's other arteries were also obstructed, raising questions about whether and when additional procedures might be undertaken.
In a study published in the Nov. 19, 2014, issue of the Journal of the American Medical Association, Duke researchers and their colleagues report the first large analysis of how often these secondary blockages ...
A novel registry study from Karolinska Institutet in Sweden suggests that beta blockers may benefit also patients suffering from a relatively unknown form of heart failure called HFPEF, which today lacks well-established treatment. HFPEF involves an impaired ability of the heart to fill with blood, and affects nearly 2% of the population. These new findings are being published in the scientific periodical JAMA.
Heart failure was for a long time defined as reduced ability to contract the heart and pump oxygenated blood out to the rest of the body. This condition is often ...
More than 40 percent of reports about energy drinks to U.S. poison control centers involved children younger than 6 with some suffering serious cardiac and neurological symptoms, according to a new study presented at the American Heart Association's Scientific Sessions 2014.
This disproportionate representation of children is concerning given the number of reports of serious cardiac and neurological symptoms, said Steven Lipshultz, M.D., the study's senior author and professor and chair of pediatrics at Wayne State University and pediatrician-in-chief at Children's Hospital ...
Recent asthma symptoms or asthma that requires daily medication may significantly raise the risk of heart attack, according to two research papers presented at the American Heart Association's Scientific Sessions 2014.
"Physicians should do all they can to control every other modifiable cardiovascular risk factor in patients with asthma," said Matthew C. Tattersall, D.O., M.S., study author and an assistant professor of medicine in the Division of Cardiology at the University of Wisconsin-Madison School of Medicine and Public Health in Madison, Wisconsin.
Tattersall's ...
Young women with stable coronary heart disease are more likely than men to have reduced blood flow to the heart if they're under emotional stress, but not physical stress, according to research presented at the American Heart Association's Scientific Sessions 2014.
Compared to men of the same age, when subjected to a mental stress test, women:
age 55 and younger had three times greater reduction in blood flow to the heart;
age 56-64 had double the reduction in blood flow to the heart; and
age 65 and older had no difference in blood flow to the heart.
"Women who ...
Breathing secondhand marijuana smoke could damage your heart and blood vessels as much as secondhand cigarette smoke, according to preliminary research presented at the American Heart Association's Scientific Sessions 2014.
In the study, blood vessel function in lab rats dropped 70 percent after 30 minutes of exposure to secondhand marijuana smoke. Even when the marijuana contained no tetrahydrocannabinol (THC) -- a compound in marijuana that produces intoxication -- blood vessel function was still impaired.
Reduced blood vessel function may raise the chances of developing ...
CHICAGO -- Patients with active asthma -- such as any use of asthma medications, and unscheduled office or emergency visits for asthma -- are at a twofold risk of having a heart attack, according to Mayo Clinic research presented at the American Heart Association's Scientific Sessions 2014.
Researchers compared 543 patients who had heart attacks with 543 non-heart attack patients of the same age and gender. These patients were treated at health care facilities in Rochester, Minnesota, between 2002 and 2006. The average age of patients was 67 years old, and 44 percent ...
